BioSpace News Archive

Teclison, today announced the peer-reviewed publication of a study demonstrating the safety, tolerability and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer.

ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that it has expanded its co-development partnership with Rgene Corporation.

Sponsored Research Agreement (SRA) with Penn advances multichain KIR-CAR platform targeting solid tumors.

Dr. Khosla brings machine-learning expertise to a company dedicated to detecting and treating gastrointestinal diseases through the applications of intelligence-based precision medicine.

Lumos Diagnostics (ASX:LDX), a leader in rapid point-of-care (POC) diagnostic technologies, announced today that its Board of Directors has appointed Doug Ward, a highly experienced diagnostics executive, to serve as CEO.

Metabolon, Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, is partnering with the University of Maryland School of Medicine to bring the latest technological advances to the School’s Amish Research Program.

Regulus Therapeutics Inc. (Nasdaq: RGLS), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022 , at 4:15 p.m. EST on Tuesday , June 28, 2022.

Bringing life-changing therapies to market requires pharmaceutical companies to efficiently design and run clinical trials, gather and analyze massive amounts of data, and manage a complicated regulatory review process.

STELLAR-303 is the first phase 3 pivotal trial evaluating XL092, a next-generation oral tyrosine kinase inhibitor.